Skip to main content

3 Result(s)

within English Remove this filter Biomedicine Remove this filter Cancer Research Remove this filter Drug Resistance Remove this filter Epidemiology Remove this filter Oncology Remove this filter J. P. Droz Remove this filter

and

  1. Article

    Open Access

    Prognostic factors for tumour response, progression-free survival and toxicity in metastatic colorectal cancer patients given irinotecan (CPT-11) as second-line chemotherapy after 5FU failure

    Our purpose was to determine, in patients with metastatic colorectal carcinoma treated with irinotecan single-agent after 5-FU failure, the most significant predictive parameters for tumour response, progressi...

    G Freyer, P Rougier, R Bugat, J-P Droz, M Marty, H Bleiberg… in British Journal of Cancer (2000)

    Download PDF (237 KB)

  2. Article

    Open Access

    A phase I/II study of 4 monthly courses of high-dose cyclophosphamide and thiotepa for metastatic breast cancer patients

    This pilot phase I/II study intended to determine the maximum tolerated dose of cyclophosphamide and thiotepa administered on four consecutive courses with peripheral blood progenitor cell and granulocyte-colo...

    T Bachelot, F Gomez, P Biron, I Ray-Coquard, P Soler-Michel… in British Journal of Cancer (2002)

    Download PDF (200 KB) View Article

  3. Article

    Open Access

    The risk of thrombo-embolic events is increased in patients with germ-cell tumours and can be predicted by serum lactate dehydrogenase and body surface area

    The aim of this study was to evaluate the risk of thrombo-embolic events (TEE) in patients with germ-cell tumours (GCT) who receive cisplatin-based chemotherapy, to compare this risk to that of a matched contr...

    A-C Piketty, A Fléchon, A Laplanche, E Nouyrigat, J-P Droz… in British Journal of Cancer (2005)

    Download PDF (115 KB) View Article